ESC Premium Access

Eligibility criteria for non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in the real world

Congress Presentation

About the speaker

Doctor Joao Andre Bicho Augusto

Barts Health NHS Trust, London (United Kingdom of Great Britain & Northern Ireland)
2 presentations
0 follower

8 more presentations in this session

Real world persistence, adherence and switch-over across anticoagulants in atrial fibrillation-a national population-based study.

Speaker: Doctor A. Banerjee (London, GB)

Thumbnail

Patients with atrial fibrillation and history of falls are at high risk for bleeding but have less bleeding with apixaban than warfarin: results from the ARISTOTLE trial

Speaker: Doctor M. Rao (Durham, US)

Thumbnail

Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and active cancer: insights from the ARISTOTLE trial

Speaker: Assistant Professor C. Melloni (Durham, US)

Thumbnail

Linking intrinsic factor X activity, a biologically relevant pharmacodynamic marker, to edoxaban plasma concentration and clinical outcomes in the ENGAGE AF-TIMI 48 trial

Speaker: Doctor O. Yin (Edison, New Jersey, US)

Thumbnail

Direct oral anticoagulants in atrial fibrillation patients undergoing cardioversion. Nationwide multicentre study.

Speaker: Miss S. Itainen-Stromberg (Helsinki, FI)

Thumbnail

Access the full session

New trends in antithrombotic therapy for atrial fibrillation

Speakers: Doctor J. Bicho Augusto, Doctor A. Banerjee, Doctor M. Rao, Assistant Professor C. Melloni, Doctor O. Yin...
Thumbnail

About the event

Image

ESC CONGRESS 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk